Merck logo

2027 Future Talent Program - Data, AI, and Genome Sciences, Precision Genetics - Co-op

Merck

South San Francisco, CAHybridPosted 2 days ago$39,908 - $111,111/year
InternshipInternBioinformatics & Data SciencePharmaceutical
Original posting ↗

Summary

The Future Talent Program within our Research & Development Division Data, AI, and Genome Sciences (DAGS) Department is offering co-op opportunities that last a period of six months. The position is in the Precision Genetics group with focus on phenotyping cardiometabolic diseases.

Job description

Precision Genetics, Cardiometabolic Diseases (South San Francisco)

  • Develop quantitative and longitudinal phenotypes from EHR using AI/ML methods in large human cohorts
  • Define clinically meaningful patient populations and translate disease concepts into reproducible biobank phenotypes
  • Assist with performing genetic analyses for drug targets identification and prioritization (GWAS, Mendelian Randomization, colocalization)
  • Build and maintain reproducible pipelines in cloud workspace

Required Education and Skills

  • Currently enrolled in a minimum of a Master's degree program in Statistical Genetics, Genetic Epidemiology, Bioinformatics, Computational Biology, Statistics, or a related field of study
  • Students enrolled in a PhD program are highly encouraged to apply
  • Available to work full-time for 6 months in 2027 as part of a formal co-op program

Preferred Skills and Experience

  • Experience with analyzing large-scale genomic datasets, including GWAS and sequencing data
  • Experience with multidimensional and longitudinal data analysis in biology or medicine and familiarity with medical coding systems (ICD, SNOMED, CPT)
  • Experience with cloud computing platforms (e.g., Databricks, AWS) and biobank research analysis platforms (e.g., UKB RAP, All of Us Workbench)
  • Proficiency in Python, SQL, R and experience with machine learning and deep learning methods
  • Track record of scientific communication and of independent research (publications, conference presentations) and strong communication skills

Requirements

  • Currently enrolled in a minimum of a Master's degree program in Statistical Genetics, Genetic Epidemiology, Bioinformatics, Computational Biology, Statistics, or a related field of study
  • Available to work full-time for 6 months in 2027 as part of a formal co-op program
  • Experience with analyzing large-scale genomic datasets, including GWAS and sequencing data
  • Experience with multidimensional and longitudinal data analysis in biology or medicine
  • Familiarity with medical coding systems (ICD, SNOMED, CPT)
  • Experience with cloud computing platforms (e.g., Databricks, AWS)
  • Experience with biobank research analysis platforms (e.g., UKB RAP, All of Us Workbench)
  • Proficiency in Python, SQL, R
  • Experience with machine learning and deep learning methods
  • Track record of scientific communication and independent research
  • Strong communication skills

Company overview

Merck & Co., Inc., known as Merck in the United States and Canada and MSD (Merck Sharp & Dohme) internationally, is a premier American multinational pharmaceutical company headquartered in Rahway, New Jersey. Founded in 1891 as the U.S. subsidiary of the German Merck Group, the company became independent following World War I and has since grown into one of the world's largest biomedical companies, ranking fourth globally by revenue. Merck operates across three core business segments: pharmaceuticals, vaccines, and animal health products. The company is renowned for its groundbreaking research and development, having brought numerous life-saving medicines to market including Keytruda (pembrolizumab), a leading immunotherapy for cancer treatment that generated $29.5 billion in 2024 revenue, and Gardasil, a revolutionary HPV vaccine. With approximately 75,000 employees worldwide, Merck maintains a robust pipeline of innovative therapies focused on oncology, vaccines, hospital acute care, cardiology, neuroscience, virology, immunology, and diabetes. The company invests heavily in R&D, spending $17.9 billion in 2024 alone, demonstrating its commitment to advancing scientific discovery. Merck's legacy spans over 130 years of bringing hope to humanity through important medicines and vaccines, operating with a purpose to use leading-edge science to save and improve lives globally while fostering an inclusive workforce and responsible business practices.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.